Please assess the completion status of the following clinical trial:

Trial Title: Fostamatinib for Hospitalized Adults With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~  1. Patient must be hospitalized, or had their inpatient stay extended, for COVID-19.~ 2. Age \>=18 years~ 3. Subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures.~ 4. Subject (or legally authorized representative) understands and agrees to comply with planned study procedures.~ 5. Females of childbearing potential must agree to be abstinent or use a medical acceptable form of contraception from the time of enrollment through 30 days after last day of study drug~ 6. Laboratory confirmed SARS-CoV-2 RT-PCR test within 7 days of enrollment~ 7. Illness of any duration with SpO2 of less than 94% on room air requiring supplemental oxygen via nasal canula or non-invasive mechanical ventilation, or mechanical ventilation or ECMO (5 to 7 on the 8-point scale)~EXCLUSION CRITERIA:~1. ALT or AST \> 5 times the upper limit of normal (ULN) or ALT or AST \>= 3 x ULN and total bilirubin \> 2 x ULN.~2. Estimated glomerular filtration rate (eGFR) \<30ml/min~3. Pregnancy or breast feeding~4. Anticipated discharge in the next 72 hours~5. Allergy to study medication~6. Uncontrolled hypertension (systolic blood pressure \>160mmHg or diastolic blood pressure \>100mmHg)~7. Shock or hypotension at the time of enrollment~8. Neutrophil count \<1000/microliter~9. Concern for bacterial or fungal sepsis~10. Received immunomodulatory treatment within 30 days prior to enrollment e.g., Bruton's tyrosine kinase/phosphoinositide 3 kinase/Janus kinase inhibitor or cytokine-targeting biologic therapy (anti-TNF, IL-6)~11. Received a live vaccine the last 4 weeks~12. Those who were cognitively impaired or mentally disabled prior to COVID diagnosis~13. Participation in another clinical trial for the treatment of COVID-19.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: ACTIVE_COMPARATOR): fostamatinib in combination with standard of care (SOC) for the treatment of COVID-19
- Intervention - Placebo (Type: PLACEBO_COMPARATOR): Placebo in combination with standard of care (SOC) for the treatment of COVID-19

Based on this trial design, predict the completion outcome and termination type (if applicable).